Gastroenterology prior authorization at Premera Blue Cross
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Premera Blue Cross gastroenterology PA at a glance
Premera Blue Cross reviews gastroenterology PA submissions against its medical policy library, with rules drawn primarily from AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target. Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet — what to send
- IBD diagnosis confirmed by endoscopy/biopsy
- Disease distribution and severity
- Prior conventional therapies tried
- Steroid course (drug, dose, taper attempts)
- Therapeutic drug monitoring labs where applicable
- Tuberculosis + hepatitis B screening prior to biologic
Common denial patterns to pre-empt
Patterns observed in gastroenterology across payers, and where Premera Blue Cross's book of business overlaps:
- Step therapy through 5-ASA / immunomodulators / steroids first
- Switching between mechanism-of-action classes without documented failure
- Therapeutic drug monitoring not done before dose escalation
- Endoscopic disease not documented
- Step therapy via Express Scripts
Appeal angles when Premera Blue Cross denies
- AGA / ACG guidelines for IBD positioning
- Endoscopic Mayo subscore or SES-CD documenting active disease
- Failure of prior biologic by mechanism of action (anti-TNF, anti-integrin, anti-IL-12/23, JAK)
- Steroid-dependence or steroid-refractory disease
Peer-to-peer prep
- Pull the most recent endoscopy report with photos if possible
- Quantify steroid dependence (mg of prednisone per year, taper attempts)
- Reference STRIDE-II treat-to-target if requesting mechanism switch
- Cite specific endoscopic scoring (Mayo, SES-CD) and the date
Drug-specific PA criteria at Premera Blue Cross
Deep dives on each drug's PA criteria at Premera Blue Cross:
Frequently asked questions
What documentation does Premera Blue Cross need for gastroenterology prior authorizations?
Premera Blue Cross's PA packet for gastroenterology typically includes: IBD diagnosis confirmed by endoscopy/biopsy; Disease distribution and severity; Prior conventional therapies tried; Steroid course (drug, dose, taper attempts). AGA / ACG / Cochrane IBD guidelines + STRIDE-II treat-to-target citations strengthen the submission.
What's the turnaround at Premera Blue Cross?
Premera Blue Cross standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which gastroenterology drugs does Premera Blue Cross most often PA-restrict?
Top targets in gastroenterology: adalimumab, infliximab, ustekinumab, risankizumab, tofacitinib. Each follows the per-drug step therapy + documentation requirements published in Premera Blue Cross's medical policy library.
How do I prep a peer-to-peer with Premera Blue Cross in gastroenterology?
Pull the most recent endoscopy report with photos if possible Quantify steroid dependence (mg of prednisone per year, taper attempts) Have the policy URL and the patient's chart open before the call.
Generate a Gastroenterology PA packet
Open ApprovalHelp — generate a gastroenterology PA packet tailored to Premera Blue Cross's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com